Ironwood's next up for the Alex Denner treatment by Carly Helfand Tuesday, April 10, 2018 Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.
After two high-profile M&A fails, how did Sanofi win Bioverativ? by Tracy Staton Friday, February 9, 2018 Sanofi didn't just woo Bioverativ execs. It made a play with investor Alex Denner. The result? $85M for CEO John Cox and a 2018 EPS boost for Sanofi.
